Follow
Chimeric antigens
Antigens are foreign substances that induce the body to generate an immune response and produce antibodies. The better the immune system can recognize antigens, the more effective immune response it can mount. Chimeric antigens are specially engineered proteins that designed to improve the ability of immune cells to target a specific disease-associated antigen.
-
FEB 15, 2024 | 8:00 AM
Macrophages can mediate phagocytosis of cancer cells and cytotoxic tumor killing, and engage in effective bidirectional interactions with components of the innate and adaptive immune system....NOV 07, 2023 | 10:00 AM
In the last 5 years, the US Food and Drug Administration has approved 4 anti-CD19 chimeric antigen receptor T cell (CART19) products for relapsed/refractory B cell lymphomas and leukemia. Ho...SEP 28, 2023 | 7:00 AM
Webinars will be available for unlimited on-demand viewing after live event. Labroots is approved as a provider of continuing education programs in the clinical laboratory sciences by the AS...JUL 26, 2023 | 3:10 PMC.E. CREDITS
Cell-based immunotherapy has become the new-generation cancer medicine, and “off-the-shelf” cell products that can be manufactured at large scale and distributed readily to treat...JUL 26, 2023 | 11:20 AMC.E. CREDITS
Chimeric antigen receptor (CAR)-reprogrammed immune cells offer exciting therapeutic potential for addressing oncology, autoimmune diseases, transplant medicine, and infections. However, cur...Speaker: Dr. Dimitrios L. WagnerPresented at: GenScript 3rd Annual Gene and Cell Engineering Summit
MAY 16, 2023 | 8:00 AM
The therapeutic use of chimeric antigen receptor T cells has achieved significant success in the treatment of B cells malignancies. Despite promising results in mouse tumor models, a similar...MAR 30, 2023 | 5:00 PM
Date: March 30, 2023 Time: 5:00pm (PST), 8:00pm (EST) March 31, 2023 9:00am (JST) Chimeric antigen receptor T cell (CAR-T) therapy is still challenging in targeting solid malignancies. The q...DEC 09, 2021 | 8:00 AM
Date: December 9, 2021 Time: 8:00am (PDT), 11:00am (EDT) Engineering human regulatory T cells (Tregs) with a chimeric antigen receptor (CAR) targeting donorderived human leukocyte antigen (H...OCT 07, 2021 | 11:55 PM
Summary: Cancer neoantigens are highly specific to the tumor, potently immunogenic and can be targeted by both vaccines and engineered cellular therapies. This talk will introduce the defini...SEP 22, 2021 | 11:59 PM
T cells exquisitely discriminate between antigenic and self-peptide ligands presented on major histocompatibility complexes (pMHCs) despite subtle differences in affinities. This aspect of a...JUL 22, 2021 | 5:00 PM
Though tumor targeting using chimeric receptors (CAR) engineered to bind tumor-associated surface proteins such as CD19 in B cells have demonstrated remarkable efficacy in cancer, this thera...JUL 08, 2021 | 8:00 AM
Date: July 8, 2021 Time: 8:00am (PDT) Cell-based chimeric antigen receptor (CAR) T cell therapies have rapidly advanced in recent years, with a variety of targets in clinical research and se...JUN 02, 2021 | 12:00 PM
Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy (CART19) occurs in 10% to 20% of patients with acute lymphoblastic leukemia (ALL); however, the mechanisms of thi...Speaker: Yong Gu Lee Ph.DJUN 02, 2021 | 12:00 AM
Learning Objectives: 1. Define “universal CARs” and describe their mechanism of action. 2. Explain current challenges in CAR T cell therapy. 3. Describe potential benefits and ch...JUN 02, 2021 | 12:00 AM
Chimeric antigen receptor (CAR) T cells have demonstrated significant success in treating relapsed or treatment-refractory hematologic malignancies in the clinic, inducing remissions in 70-9...JUN 02, 2021 | 12:00 AM
Rhabdomyosarcoma (RMS) is a soft tissue cancer commonly arising in muscle and is the most common soft tissue cancer in children. Patients with metastatic RMS have a poor prognosis that has n...APR 08, 2021 | 10:00 AM
Cell therapies, including chimeric antigen receptor (CAR) T-cell therapy, are emerging as promising treatments, especially for hematological malignancies. However, many challenges remain in...Speaker: Adriana Suarez, Ph.D.SEP 23, 2020 | 12:00 PM
B cells and tertiary lymphoid structures (TLS) promote immunotherapy response 1:00–1:30 pm PDT Presented By: Rafet Basar, MD...Speaker: Handan Xiang, PhD , Pei-Yu Chen, PhD , Hiranmayi Ravichandran, MS , Rafet Basar, MD , Amir Horowitz, PhDPresented at: 9th Annual Fluidigm Mass Cytometry Virtual Summit
SEP 23, 2020 | 6:30 AM
Single-cell mass cytometry identifies mechanisms of resistance to immunotherapy in AML 6:30–7:00 am PDT Presented By: Shelley Herbrich, PhD Understanding CD19 negative relapse followin...Speaker: Shelley Herbrich, PhD , Kara L. Davis, DO , Bernd Bodenmiller, PhDPresented at: 9th Annual Fluidigm Mass Cytometry Virtual Summit
SEP 08, 2020 | 9:00 AM
Seasonal and pandemic influenza virus infections can cause significant disease worldwide. Current vaccines only provide limited, short-lived protection, and antigenic drift/shift in the hema...JUL 29, 2020 | 2:00 PM
B7-H3 is actively being explored as an immunotherapy target for pediatric patients with solid tumors using monoclonal antibodies or T cells expressing chimeric antigen receptors (CARs). B7-H...Speaker: Christopher DeRenzo, MDPresented at: Immuno-Oncology & Cancer Biology Virtual Conference
JUL 29, 2020 | 9:00 AM
Advances in genetic engineering have improved specificity, safety and potency of T-cell receptor (TCR) and Chimeric Antigen Receptor (CAR-T) based therapies for solid and non-solid tumours....Speaker: Juan Miguel Sanchez Nieto, PhDPresented at: Immuno-Oncology & Cancer Biology Virtual Conference
FEB 25, 2020 | 9:00 AM
Learn about how to generate a small scale CAR-T workflow using ThermoFisher products See detailed characterization tools that can be utilized and applied in a CAR-T workflow...SEP 18, 2018 | 8:00 AM
DATE: September 18,2018TIME: 08:00am PDT, 11:00am EDT CRISPR-Cas9 gene editing strategies have revolutionized our ability to engineer the genomes of diverse cell types and sp...
FEB 15, 2024 | 8:00 AM
Macrophages can mediate phagocytosis of cancer cells and cytotoxic tumor killing, and engage in effective bidirectional interactions with components of the innate and adaptive immune system....
NOV 07, 2023 | 10:00 AM
In the last 5 years, the US Food and Drug Administration has approved 4 anti-CD19 chimeric antigen receptor T cell (CART19) products for relapsed/refractory B cell lymphomas and leukemia. Ho...
SEP 28, 2023 | 7:00 AM
Webinars will be available for unlimited on-demand viewing after live event. Labroots is approved as a provider of continuing education programs in the clinical laboratory sciences by the AS...
JUL 26, 2023 | 3:10 PM
C.E. CREDITS
Cell-based immunotherapy has become the new-generation cancer medicine, and “off-the-shelf” cell products that can be manufactured at large scale and distributed readily to treat...
JUL 26, 2023 | 11:20 AM
C.E. CREDITS
Chimeric antigen receptor (CAR)-reprogrammed immune cells offer exciting therapeutic potential for addressing oncology, autoimmune diseases, transplant medicine, and infections. However, cur...
Speaker:
Dr. Dimitrios L. Wagner
Presented at: GenScript 3rd Annual Gene and Cell Engineering Summit
MAY 16, 2023 | 8:00 AM
The therapeutic use of chimeric antigen receptor T cells has achieved significant success in the treatment of B cells malignancies. Despite promising results in mouse tumor models, a similar...
MAR 30, 2023 | 5:00 PM
Date: March 30, 2023 Time: 5:00pm (PST), 8:00pm (EST) March 31, 2023 9:00am (JST) Chimeric antigen receptor T cell (CAR-T) therapy is still challenging in targeting solid malignancies. The q...
DEC 09, 2021 | 8:00 AM
Date: December 9, 2021 Time: 8:00am (PDT), 11:00am (EDT) Engineering human regulatory T cells (Tregs) with a chimeric antigen receptor (CAR) targeting donorderived human leukocyte antigen (H...
OCT 07, 2021 | 11:55 PM
Summary: Cancer neoantigens are highly specific to the tumor, potently immunogenic and can be targeted by both vaccines and engineered cellular therapies. This talk will introduce the defini...
SEP 22, 2021 | 11:59 PM
T cells exquisitely discriminate between antigenic and self-peptide ligands presented on major histocompatibility complexes (pMHCs) despite subtle differences in affinities. This aspect of a...
JUL 22, 2021 | 5:00 PM
Though tumor targeting using chimeric receptors (CAR) engineered to bind tumor-associated surface proteins such as CD19 in B cells have demonstrated remarkable efficacy in cancer, this thera...
JUL 08, 2021 | 8:00 AM
Date: July 8, 2021 Time: 8:00am (PDT) Cell-based chimeric antigen receptor (CAR) T cell therapies have rapidly advanced in recent years, with a variety of targets in clinical research and se...
JUN 02, 2021 | 12:00 PM
Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy (CART19) occurs in 10% to 20% of patients with acute lymphoblastic leukemia (ALL); however, the mechanisms of thi...
Speaker:
Yong Gu Lee Ph.D
JUN 02, 2021 | 12:00 AM
Learning Objectives: 1. Define “universal CARs” and describe their mechanism of action. 2. Explain current challenges in CAR T cell therapy. 3. Describe potential benefits and ch...
JUN 02, 2021 | 12:00 AM
Chimeric antigen receptor (CAR) T cells have demonstrated significant success in treating relapsed or treatment-refractory hematologic malignancies in the clinic, inducing remissions in 70-9...
JUN 02, 2021 | 12:00 AM
Rhabdomyosarcoma (RMS) is a soft tissue cancer commonly arising in muscle and is the most common soft tissue cancer in children. Patients with metastatic RMS have a poor prognosis that has n...
APR 08, 2021 | 10:00 AM
Cell therapies, including chimeric antigen receptor (CAR) T-cell therapy, are emerging as promising treatments, especially for hematological malignancies. However, many challenges remain in...
Speaker:
Adriana Suarez, Ph.D.
SEP 23, 2020 | 12:00 PM
B cells and tertiary lymphoid structures (TLS) promote immunotherapy response 1:00–1:30 pm PDT Presented By: Rafet Basar, MD...
Speaker:
Handan Xiang, PhD
, Pei-Yu Chen, PhD
, Hiranmayi Ravichandran, MS
, Rafet Basar, MD
, Amir Horowitz, PhD
Presented at: 9th Annual Fluidigm Mass Cytometry Virtual Summit
SEP 23, 2020 | 6:30 AM
Single-cell mass cytometry identifies mechanisms of resistance to immunotherapy in AML 6:30–7:00 am PDT Presented By: Shelley Herbrich, PhD Understanding CD19 negative relapse followin...
Speaker:
Shelley Herbrich, PhD
, Kara L. Davis, DO
, Bernd Bodenmiller, PhD
Presented at: 9th Annual Fluidigm Mass Cytometry Virtual Summit
SEP 08, 2020 | 9:00 AM
Seasonal and pandemic influenza virus infections can cause significant disease worldwide. Current vaccines only provide limited, short-lived protection, and antigenic drift/shift in the hema...
JUL 29, 2020 | 2:00 PM
B7-H3 is actively being explored as an immunotherapy target for pediatric patients with solid tumors using monoclonal antibodies or T cells expressing chimeric antigen receptors (CARs). B7-H...
Speaker:
Christopher DeRenzo, MD
Presented at: Immuno-Oncology & Cancer Biology Virtual Conference
JUL 29, 2020 | 9:00 AM
Advances in genetic engineering have improved specificity, safety and potency of T-cell receptor (TCR) and Chimeric Antigen Receptor (CAR-T) based therapies for solid and non-solid tumours....
Speaker:
Juan Miguel Sanchez Nieto, PhD
Presented at: Immuno-Oncology & Cancer Biology Virtual Conference
FEB 25, 2020 | 9:00 AM
Learn about how to generate a small scale CAR-T workflow using ThermoFisher products See detailed characterization tools that can be utilized and applied in a CAR-T workflow...
SEP 18, 2018 | 8:00 AM
DATE: September 18,2018TIME: 08:00am PDT, 11:00am EDT CRISPR-Cas9 gene editing strategies have revolutionized our ability to engineer the genomes of diverse cell types and sp...